Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Carboplatin in Anaplastic Prostate Carcinoma
NCT00514540Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2006
- Primary completion
- Apr 2013
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, carboplatin, etoposide, Cisplatin micelle injection (HA132) in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started May 2006; status: completed.
02
Drugs
docetaxelcarboplatinetoposideCisplatin micelle injection (HA132)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00514540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514540.